The present invention relates generally to a system and a method for assessing urinary function. More particularly, the system and method is used for testing the integrity of the urinary system for diagnostic purposes, and in particular for diagnosing urge incontinence.
Women account for more than 11 million of incontinence cases. Moreover, a majority of women with incontinence suffer from stress urinary incontinence (SUI). Women with SUI involuntarily lose urine during normal daily activities and movements, such as laughing, coughing, sneezing and regular exercise.
SUI may be caused by a functional defect of the tissue or ligaments connecting the vaginal wall with the pelvic muscles and pubic bone. Common causes include repetitive straining of the pelvic muscles, childbirth, loss of pelvic muscle tone and estrogen loss. Such a defect results in an improperly functioning urethra. Unlike other types of incontinence, SUI is not a problem of the bladder.
Normally, the urethra, when properly supported by strong pelvic floor muscles and healthy connective tissue, maintains a tight seal to prevent involuntary loss of urine. When a woman suffers from the most common form of SUI, however, weakened muscle and pelvic tissues are unable to adequately support the urethra in its correct position. As a result, during normal movements when pressure is exerted on the bladder from the diaphragm, the urethra cannot retain its seal, permitting urine to escape. Because SUI is both embarrassing and unpredictable, many women with SUI avoid an active lifestyle, shying away from social situations.
SUI is categorized into three types. Type I and Type II are directed to urethral hypermobility. Type III is directed to intrinsic sphincter deficiency (ISD). Diagnosis of ISD requires urodynamic evaluation. Urodynamic evaluation involves complex and invasive equipment and often requires referral to a specialist trained in urodynamic evaluation.
Existing diagnostic systems all require a catheter be passed trans-urethraly to measure pressure, such as Leak Point Pressure (LPP) or Urethral Pressure Profile (UPP). An exemplary system is disclosed in publication (WO 0023127). Detection of LPP requires that a pressure sensor and catheter be passed trans-urethrally. The bladder is filled, and pressure is recorded. Fluid leakage from the urethral opening (meatus) corresponds to the maximum pressure the urethral sphincter can resist, or LPP. During the UPP measurement procedure a pressure sensor tipped catheter is placed trans-urethral into the bladder and then withdrawn at a constant velocity. The pressure profile along the urethra, from bladder neck to meatus is recorded.
Other parameters may also be measured, such as abdominal pressure and urinary flow. A cystometrogram (CMG) is a pressure study that simultaneously measures intra-abdominal, total bladder, and true detrusor pressures. Uroflometry measures urine flow rate visually, electronically, or via a disposable system. Video Urodynamic Systems also exist that simultaneously measure parameters, as described above, with radiographic visualization of the lower urinary-tract.
Existing urodynamic evaluation systems are complex, expensive, and require extensive training. Furthermore, existing urodynamic systems often require at least 30 minutes to complete a test. This exceeds the time available for most standard physician office visits and results in referral to a specialist. No urodynamic system exists that can quickly and inexpensively record useful urodynamic measures, without passing a catheter or instrument trans-urethraly.
Other than SUI, urge incontinence also accounts for a great number of cases of urinary incontinence. Urge incontinence is caused by overactive bladder muscles. Detrusor instability is one cause of urge incontinence. Detrusor instability involves spontaneous and unprovoked involuntary contractions of the detrusor muscle (the muscles that make up the bladder wall) during filling of the bladder that cannot be suppressed. Currently, diagnosis of detrusor instability similarly involves the use of invasive and uncomfortable transurethral catheters. The bladder is filled with fluid using such catheters, and the pressure is monitored to detects spikes in pressure, which indicate detrusor muscle contractions. Diagnosis using transurethral catheters is often complicated by the fact that the catheter often aggravates the delicate muscle structures of the urethral sphincter and bladder neck. Thus, the transurethral catheter actually aggravates and disrupts the very structures that the measurements seek to evaluate, potentially giving misleading results.
With regard to urge incontinence, there remains a need for an improved system and method for assessing detrusor instability.
The present invention provides a method for diagnosing detrusor instability including the steps of using an insert member having a channel therethrough positioned distal of the urethral sphincter, creating a substantially fluid tight seal to substantially block fluid flow into or out of the urethral canal other than through the channel, infusing fluid from a fluid source through the channel in the insert member and into the urethral canal at a location distal of the urethral sphincter, and measuring a pressure within the urethral canal at a location distal of the urethral sphincter as the fluid is being infused therein, wherein the infusing step further includes infusing fluid until the urethral sphincter opens, and thereafter until at least one detrusor contraction occurs. In alternate embodiment, the fluid is infused at rate of approximately 40-120 mL/min, and/or the fluid is infused for at least approximately 3 minutes.
In one embodiment, the method further includes providing data correlating to the measured pressure to a processor, and displaying on a display device measured pressure versus time. In yet another embodiment, at least a distal portion of the insert member is substantially conical in shape, and the insert member channel may also include an insert member channel inlet at a proximal end and an insert member outlet at a distal end including a plurality of apertures spaced apart about an outer surface of the distal end of the insert member.
In yet another embodiment, the insert member is coupled to a device for diagnosing urinary incontinence that includes a control device having a processor and a pump therein, and a test module removably coupled to the control device. The test module includes a tubing assembly coupled to the pump for pumping fluid therethrough, and having a first fluid conduit between a fluid inlet and a fluid outlet, the fluid outlet being coupled to the insert member and in fluid communication with the insert member channel. The fluid inlet of the first fluid conduit may be coupled to a fluid source. In another embodiment, the control device further includes a pressure sensor, and the test module further includes a pressure interface in fluid communication with the first fluid conduit and in communication with the pressure sensor so as to transmit pressure information thereto.
A method for diagnosing detrusor instability is also provided including coupling a test module to a control device, the test module including a tubing assembly having a first fluid conduit between a first fluid inlet and a first fluid outlet, and an insert member coupled to the first fluid outlet and having a channel therethrough in communication with the first fluid conduit so that fluid flowing through the first fluid conduit can flow through the insert member, coupling the first fluid inlet to a fluid source, inserting the insert member at least partially into a patient's urethral canal at a location distal of the urethral sphincter so as to substantially block fluid flow into or out of the urethral canal other than through the insert member channel, infusing fluid from the fluid source into the urethral canal through the first fluid conduit and insert member; and measuring the pressure within the urethral canal at a location distal of the urethral sphincter as the fluid is being infused therein, wherein, the infusing step further includes infusing fluid into the urethral canal until the urethral sphincter opens, and thereafter until at least one detrusor muscle contraction occurs.
Yet another method for diagnosing detrusor instability is provided including the steps of inserting an insert member having a channel therethrough at least partially into a patient's urethral canal at a location distal of the urethral sphincter, the insert member being dimensioned to substantially block fluid flow into and out of the urethral canal other than through the insert member channel, infusing fluid from a fluid source through the insert member channel and into the urethral canal at a location distal of the patient's urethral sphincter at a rate of approximately 40-120 mL/min, measuring pressure within the urethral canal at a location distal of the urethral sphincter as fluid is being infused therein, and providing data correlating to the measured pressure to a processor, wherein the infusing step further includes infusing fluid until the urethral sphincter opens, and thereafter until at least one detrusor contraction occurs.
These and other features and advantages of the present invention will become apparent from the following more detailed description, when taken in conjunction with the accompanying drawings which illustrate, by way of example, the principles of the invention.
a is a front view of one embodiment of a portable medical system according to the present invention;
a is an exploded perspective view of one embodiment of a pole attachment mechanism;
b is a rear perspective view of the pole attachment mechanism of
c is a rear view of the pole attachment mechanism of
d is a rear view of the pole attachment mechanism of
a is a schematic cross-sectional view taken across line 5a-5a of
b is a schematic cross-sectional view similar to
a-8j are flow diagrams illustrating operation of control device software and graphical user interface components;
a is a partial cross-sectional view of one embodiment of a portable medical system including an SUI module;
b is an enlarged view illustrating a pressure transducer and filter according to one embodiment of the present invention;
a is a side elevational view and partial cross-section of one embodiment of a hand actuator in an assembled configuration;
b is a side elevational view and partial cross-section of the hand actuator of
c is a side elevational view and partial cross-section of the hand actuator of
d is an alternative embodiment of a hand actuator according to the present invention;
Referring now to
The control device 102 includes a housing 112 for housing various components, including one or more batteries 114, an electronics assembly 116, a pump device 118 including a motor, and various other circuitry. Batteries supply power to the control device 102, and are contained within a battery compartment 120 that is accessible by removing the battery cover 122 that forms part of the housing 112. The control device further includes an input keypad 108 for allowing a user to input data (such as patient name or other identifier, numeric identifiers, patient history, date etc.) and an input pendant 106 including one or more switches 124 that allow user input of additional information (i.e., event input based on patient feedback), and an activation switch 126 for turning the device on and off. The pump device 118 and at least one pressure transducer 128 are also contained within the housing. The pump device is electrically coupled to the battery and the electronics assembly, and the pressure transducer is electrically coupled to the electronics assembly. The control device 102 may also include a pole mounting mechanism 400 for mounting the control device on a pole such as the pole of an IV solution caddy 402 including a hook 404. One embodiment of a pole mounting mechanism is illustrated in
As indicated above, any one of a plurality of modules 104, such as diagnostic test modules, can be removably coupled to the control device 102, and the control device is designed to uniquely identify the attached module, and perform routines specific to that module. Thus, the control device includes a module detection mechanism 500 capable of identifying the attached module that is electrically coupled to the electronics assembly (see
The module further includes at least one coupling element 600 for removably coupling the module to the control unit (see
Finally, the module housing 506 includes first 608 and possibly second 610 ports therein as shown in
As indicated above, contained within the housing 112 of the control device 102 is an electronics assembly 116 (see
The microprocessor 710 is programmed with a custom program file. In the illustrated embodiment, this software has multiple functions. First is the acquisition of input from the operator. This input data is captured from the input keypad 108, and/or switches 124, 126, pressure transducer(s) or other input device, depending upon which test module is in use. The software also controls operation of the pump device 118. Input data is interpreted and appropriate signals are sent to the pump device motor via the integrated circuit board 702. Yet another function is to acquire and condition data from the pressure transducer(s). This data is then sent in the appropriate format to the display 110, along with applicable pump device data in the form of volume or time information. Finally, as indicated above, the software receives input from the module detection mechanism 500 and interprets this input to determine which test module is coupled to the control device.
a-8i are flow diagrams illustrating operation of the diagnostic system software and features of the system graphical use interface for a preferred embodiment of the invention. When the system is powered on, the user is first presented with a welcome screen. While this screen is being displayed the system is undergoing a self-test routine 802 to test the integrity of system hardware and software components. Upon completion of this routine, the user is provided with information relating to the amount of available system memory 804. Following the pressing of any key 806 on input device 108 by the user, the system identifies the attached module 808 as described above, and following such identification, the processor executes a software subroutine specific to the identified module. For each software subroutine, however, a main menu is displayed next, such as that indicated by reference numeral 810. In the illustrated embodiment, the main menu includes six possible selections. “Utilities” enables the user to access various system features, such as setting the date, time etc, or adjusting the brightness or contrast of the screen; “Quit” terminates the session; “Patients” enables the user to access any previously stored data relating to other patients and tests already performed; “Prime” initiates the pump priming process; “Patient ID” enables the user to enter a patient identification number; and “Test” initiates a software subroutine specific to the attached module to carry out the desired test procedure. In the presently described embodiment, the software and user interface associated with the “Prime,” “Utilities,” “Quit,” and “Patient ID” selections are substantially the same for each software subroutine. The “Test” and “Patients” selections, however, are different for each test module. Each of these selections will be described in greater detail below.
As is illustrated in
Before performing any test that requires fluid to be infused into the patient, priming operations must be performed to ensure that the fluid infusion lines (tubing) are filled with fluid and not air. Referring now to
With priming complete, testing can begin. As indicated above, testing procedures depend on the attached test module, and accordingly, the software and graphical user interfaces relating to each test module will be discussed in greater detail below in conjunction with the detailed description of each test module.
In an alternative embodiment of the invention illustrated in
As indicated above, the diagnostic system described herein has particular application to urodynamics in that it enables clinicians to diagnose a plurality of urinary incontinence problems when used with specifically designed testing modules (to be discussed hereinafter). As a miniaturized urodynamic tool, the control device 102 in conjunction with modules 104 can measure urethral resistance pressure (URP), detrusor instability (DI), voiding flow (Uroflometry), and bladder dysfunction (Cystometrogram (CMG)). As will be described further below, URP is a new and unique approach to urodynamic measurement of stress incontinence that is less invasive for a patient, and faster than currently known and used diagnostic tests. Uroflometry is the study of micturation over time. CMG is the study of bladder or detrusor instability. A major advantage of the diagnostic system disclosed herein is that it can achieve all of the diagnostic tests described above with a portable unit that can be used in any office exam room, removing the need for the reservation or scheduling of a specialized urodynamic room, and the need for the complex equipment currently required for such tests. The urodynamic system is easy to use and does not require advance training. Use of the disclosed system makes testing more comfortable for patients by enabling faster set up, shorter test time, and less invasive procedures.
In actual use, different modules can be removably coupled to the control device 102 to conduct these different urodynamic tests. Each module performs a different and distinct test. These modules include, but are not limited to, a stress urinary incontinence (SUI) module for measurement of urethral resistance pressure (URP); a simple CMG module for measurement of bladder instability; a complex CMG module for measurement of bladder instability; detrusor instability module (DI) which measures detrusor instability in a different and non-invasive manner relative to CMG, and a uroflometry module for the study of micturation over time. Modules may be suitably adapted to either male or female incontinence diagnosis.
Before proceeding with a discussion of individual test modules, to assist the reader a brief overview of the female urinary system will be described with reference to
Individual testing modules will now be described in detail.
The SUI testing module 1000 tubing assembly also includes a second tubing member 1025 having a channel therethrough forming a second fluid conduit between a proximal end 1026 and a distal end 1028.
Referring now to
In one embodiment, the hand actuator further includes a hand-sized housing or casing 1102 including therein an initiator element 1118 (
The hand actuator 1100 further includes a fluid conduit 1050 extending between an outlet 1195 and an inlet 1194 that is coupled to (integrally or otherwise) an external tubing conduit leading to a fluid source, such as the first fluid conduit 1010 of the SUI test module. Alternatively, the hand actuator may be designed to include therein the fluid source. The fluid outlet 1195 is in fluid communication with the insert member channel of the meatus plug device. An activation device 1127 including a trigger 1128 extends through an opening 1118a to an exterior of the casing. The activation device 1127 is movable between a first rest position (shown) and a second activated position. In the first position spring 1130 exerts force on coupling member 1132, causing it to pivot relative to pivot element 953 and pinch the distal ends of at least tubing member 1050 to prevent fluid flow therethrough. When in the second position, movement of the trigger causes the coupling member 1132 to pivot to a point at which it no longer pinches tubing member 1050. Further, trigger 1128 may also compresses air bladder 1097 to initiate testing as described above in connection with initiator element.
The plug element 1108 is configured so that, when inserted into the urethral meatus of a patient (see
The first fluid conduit 1010 of the tubing assembly also includes an elongated single lumen tubing member 1032 having a first end 1006 and a second end 1034 and a fluid channel extending therethrough. A spike device 1036 is coupled to the first end 1006 of the single lumen tubing member for attachment to a fluid bag 1038 (having a fluid 1010 therein) in a manner well known in the art. As described above, the meatus plug device and first fluid conduit are coupled to one another such that fluid from the fluid source traveling through the first fluid conduit may pass through the insert member (via the channel therein) and into the urethral canal distal of the urethral sphincter. Further, as the first pressure interface 1024 is in fluid communication with the first fluid conduit and ultimately the urethral canal, pressure at the pressure interface substantially corresponds to the pressure within the urethral canal distal of the urethral sphincter.
Use of the system 100 including a SUI testing module 1000 is as follows. First, the SUI testing module is removably coupled to the control device 102 in the manner described above. The physical coupling causes the identification probes 502 of the control unit to engage the module identification element(s) 504 of the SUI testing module, enabling the control device to identify the SUI testing module. The physical coupling also brings pressure interface 1024 in physical contact with pressure transducer 128 as described above so that pressure changes at the pressure interface can be detected by the pressure transducer and transmitted to the electronics assembly for interpretation. The pressure interface 1026a at the proximal end of tubing member 1025 similarly comes in contact with pressure transducer 1030 so that pressure within tubing member 1025 can also be detected. Finally, the tubing loop 1012 is brought into physical contact with the pump device 118 so that the pump device can drive fluid through the first fluid conduit by peristaltic motion, as described above.
As shown in
The meatus plug 1102 is inserted into the meatus of the urethra (2025) and the test is started (2030) by pressing the activation button as described above. This in turn sends instructions to the pump device via the integrated circuit. The pump device then pumps fluid 1040 through the first fluid conduit 1010 and meatus plug device channel 1112 and into the urethral canal distal of the urethral sphincter (2035). As fluid pressure builds in the urethral canal 1302, pressure in the pressure chamber 1016 also builds. This pressure is transmitted through the filter component 1022 and pressure interface 1024 to the pressure transducer 128, which receives the pressure data and transcribes it into an electrical signal. The electrical signal from the pressure transducer is sent to the microprocessor 710 via the integrated circuit 702 where it is acquired and conditioned. The information is then sent to the display 110 via the integrated circuit. The microprocessor ends the test after a specified amount of time, or upon receipt of input from the user by sending an “off” signal to the pump motor drive. Once the test has been completed, the operator disengages the activation button 1118 (step 2040) and removes the meatus plug element from the meatus 1304 (2045).
Referring once again to
Once the final URP value is displayed, a Save/Delete screen 874 is overlayed on the screen. If the user selects the “Save” option, the test results are saved in memory. If the user selects “Delete” from the Save/Delete screen 874, the user is then presented with the Save Test screen 876. If “Delete” is chosen the test is deleted, but if “Cancel” is selected, the user is returned to the Save/Delete screen.
According to one embodiment, test results for up to three out of six possible tests may be stored. Once three tests have been stored or six tests have been run, whichever comes first, the control unit 102 will disable the module identification component 504 via the identification probes 502. After testing is complete, the user may return to the main menu by selecting the “Menu” option from the Test Complete screen.
One option available from the Main Menu, as stated above, it “Patients,” which allows the user to access patient and test data previously stored. According to one embodiment illustrated in
As indicated above, the results obtained from the SUI test is the urethral resistance pressure (URP), which is the back-pressure necessary to force open the urethral sphincter muscle 1306 from the reverse or opposite direction from which fluid normally flows. A major advantage of the SUI testing module 1000 is that the insert or plug element 1108 of the meatus plug device 1102 only enters the external urethral canal (meatus) and does not cause any discomfort associated with passing a catheter through the internal urethral sphincter. Thus, the diagnostic system disclosed herein having a SUI module 1000 is less invasive and more comfortable for patients. Further, the testing procedure for the SUI module 1000 is easy to implement, quick to perform, and does not require advance training by the clinician and/or physician.
Diagnosis of detrusor instability can be performed utilizing a module substantially identical to the SUI module described above and in a substantially identical manner, but with only minor modifications to the software (hereinafter referred to as the “DI” test or module). This diagnostic test is an alternative, less invasive test for determining detrusor instability as compared to the CMG test described in detail below. As indicated above and as illustrated in
A representative graph is shown in
Referring now again to
The above described method for diagnosing detrusor instability is less invasive, quicker, and more reliable than currently known methods. The present method avoids the need for invasive and uncomfortable transurethral catheters. Further, the results are more reliable in that there is no false or exaggerated detrusor activity caused by the presence of such a catheter.
The diagnostic system disclosed herein can also be used to perform both simple and complex cystometrograms.
Referring now to
Use of the diagnostic system to perform a SCMG will now be described in detail with reference to
Once the SCMG testing module 1400 is coupled to the control device 102, the operator enters input data appropriate for the SCMG test (2115). This data is received and interpreted by the microprocessor 710 and applicable information is sent by the microprocessor to the display 110. Priming operations are then performed (2120). At this point, the microprocessor is ready to start the test routine.
The dual lumen catheter 1422 is then inserted into the bladder 1308 (2125) via the urethra 1304 and the test is started by pressing the input pendant switches 124 (2130). The microprocessor 710 receives the signal from the input pendant switches. Instructions are then sent to the pump device 118 via the integrated circuit 702. The pump device then pumps fluid through the first fluid conduit 1402 and tubing element 1418 into the bladder (2135). As fluid volume builds in the bladder, pressure in the bladder also builds. This pressure is transmitted through tubing member 1420 and the second conduit 1408, filter component 1022b, and pressure interface 1024b. The pressure transducer 128 receives the pressure data and transcribes it into an electrical signal. The electrical signal from the pressure transducer 128 is sent to the microprocessor 710 via the integrated circuit board 702 where it is acquired and conditioned. During the course of a typical SCMG test, the patient provides event input, such as feeling the need to void and/or the intensity of that feeling, which is input to the control device via input pendant switches 124, as will be described more fully below. The microprocessor ends the test (2140) after a specified amount of time, or upon receipt of an “off” signal from input pendant switch 124. Once the test has been completed, the operator and removes the catheter 1422 from the bladder (2145). Following the test the software then exits the SCMG test subroutine, and the data storage routine is run to store and/or display results of the test.
Referring again to
As the bladder is filling, the patient communicates the point in time at which he/she feels the initial sensation of needing to void, and the user presses the input pendant switch 124 to mark this point in time 873a. The fluid infusion continues, and the user then marks the point in time at which the patient feels the urge to void 874a, and the point at which the patient feels an extreme, almost unbearable urge to void 875a, or has voided. Upon this third marking, the fluid infusion ceases and the test is completed 876a. During fluid infusion and after the test is complete, a graph is displayed illustrating pressure versus volume infused. After completion of the test a Save/Delete overlay 877 appears. Selecting “Save” and pressing enter saves the test data. Selecting “Delete” causes a Save/Delete screen 878 overlay to appear. Selecting “Delete” from this screen deletes the data, where as selecting “Cancel” from this screen returns to the Save/Delete overlay.
At any point between initiating pumping and completing the SCMG test, the user may pause the test by depressing and holding, or pressing firmly on the input pendant switch 880, which causes the pump device to stop pumping fluid into the patient's bladder, and a Pause screen 881 (
In reference to
Use of the diagnostic system to perform a CCMG will now be described in detail with reference to
Once the CCMG testing module 1700 is coupled to the control device 102, the operator enters input data appropriate for the CCMG test (2215). This data is received and interpreted by the microprocessor 710 and applicable information is sent by the microprocessor to the display 110. Priming operations are then performed (2220
The dual lumen catheter 1422 is inserted into the bladder via the urethra 1302 (2225). The single lumen catheter 1702 is inserted into either the vagina or the rectum (2230) and the test is started (2235) by pressing the input pendant switches 124. The microprocessor 710 receives the signal from the input pendant switches. This in turn sends instructions to the pump device 118 via the integrated circuit 702, and the pump device pumps fluid through the first tubing conduit 1042 and tubing element 1418 into the bladder (2240). As fluid volume builds in the bladder, pressure in the bladder also builds. This pressure is transmitted through pressure interface 1024b to pressure transducer 128. Similarly, abdominal pressure is transmitted through pressure interface 1024c to pressure transducer 1030. The pressure transducers receive the pressure data and transcribe it into electrical signals. The electrical signals are sent to the microprocessor 710 via the integrated circuit board 702 where it is acquired and conditioned. The microprocessor ends the test after a specified amount of time or upon receipt of an “off” signal from input pendant switches 124 (2245). Once the test has been completed, the operator disengages the input pendant switches and removes the catheters 1422 and 1702 from the bladder (2250). The stored information is then available for review on the display screen, or by a print out through a charging cradle (printer assembly), or downloaded to a PC via a software interface in the charging cradle.
Referring again to
Both the SCMG and CCMG testing modules 1400 and 1700 provide a simple, relatively low cost procedure for recording a cystometrogram (CMG). The SCMG and CCMG testing modules are sterile, disposable assemblies that eliminate the need to disinfect equipment prior to use. This, together with a relatively simple set-up and operational procedure by the physician, greatly reduces the time required to obtain the urodynamic data. The SCMG and CCMG testing modules are more comfortable for the female patient and are more cost effective for the physician. The simplicity of the SCMG and CCMG testing modules, and the control device 102 allows operation with minimal training. Further, when combined in operational use with the SUI testing module 1000, these modules provide a near complete urodynamic diagnostic tool for the physician.
A uroflometry testing module 2400 can also be removably coupled to control device 102. The module housing of the uroflometry testing module 2400 may be in the form of a plastic disposable cartridge. As shown in
The diagnostic system including the Uroflometry testing module is operated as follows. The collection bucket is positioned under a commode 2412 to collect urine as the patient voids. Balloon is positioned relative to the bucket so that it substantially supports the bucket. As the bucket fills the pressure in the balloon rises proportionately to the weight of the fluid. When the testing module is coupled to the control device, the proximal end 2404 of the single lumen tubing member 2402 contacts the pressure transducer 128 of the control device 102 so that the pressure within the balloon can be captured and interpreted by the control device. The pressure data is used to calculate the weight and volume of the fluid (known fluid density). The stored information is then available for review on the display screen, or by a printout through a charging cradle (printer assembly), or downloaded to a PC via a software interface in the charging cradle. Once the test has been completed, the operator disengages the input pendant switches 124, and the urine and collection bucket are discarded.
Operation of the Uroflometry module software subroutine is illustrated in
Current medical practice calls for the use of a vaginal speculum secured in place in order to reduce the prolapse. For example, U.S. Pat. Nos. 5,997,474 and 6,048,308 describe specula specifically designed for vaginal examination and treatment. U.S. Pat. No. 6,120,438 discloses a vaginal retractor device designed to hold back the vaginal wall during an exam or surgical procedure. Often, surgical tape is necessary to hold the speculum in place, as the physician's hands cannot hold the speculum in place while performing a particular urodynamic procedure. None of the prior art speculum devices integrate the use of urodynamic equipment.
With reference to
Although a particular embodiment of the connector member 2602 is illustrated and described herein, those skilled in the art will recognize that various other embodiments are also possible to provide a means by which to removably couple a device that is inserted into the urethral canal to the speculum so as to hold it in place within the patient.
In operation, the vaginal speculum assembly 2600 can be cooperatively used in conjunction with the urodynamic system disclosed herein. For example, it may be used in conjunction with a urodynamic system including a SUI testing module 1000 in the performance of the urodynamic testing procedure for stress urinary incontinence (SUI), such as the measuring of urethral resistance pressure (URP) as previously described. In reference to
Although the portable medical system disclosed herein has been described in conjunction with diagnostic testing, it is to be understood that the system can also be used in conjunction with therapies and/or surgical procedures for treating urinary incontinence, such as placement of a sling, placement of bulking agents, shrinkage of tissue etc. In this regard, the testing described herein can be used before, during and/or after these procedures to ensure success of the procedures, for example, to ensure correct placement and/or tensioning of a sling.
Although exemplary embodiments and methods for use have been described in detail above, those skilled in the art will understand that many variations are possible without departing from the spirit and scope of the invention, which is limited only by the appended claims.
The present invention is a continuation-in-part of earlier filed U.S. patent application Ser. No. 10/183,790, filed on Jun. 27, 2002, now U.S. Pat. No. 7,052,452 which claims the benefit of earlier filed U.S. provisional patent applications, Ser. Nos. 60/302,069, filed on Jun. 29, 2001 and 60/372,579, filed on Apr. 12, 2002, all of which are incorporated by reference in their entirety herein.
Number | Name | Date | Kind |
---|---|---|---|
926197 | Kim | Jun 1909 | A |
1666332 | Hirsch | Apr 1928 | A |
1688795 | Aas | Oct 1928 | A |
1819368 | Hart | Aug 1931 | A |
3685787 | Adelberg | Aug 1972 | A |
3699964 | Ericson | Oct 1972 | A |
3789835 | Whitman | Feb 1974 | A |
3812841 | Isaacson | May 1974 | A |
3900184 | Burke et al. | Aug 1975 | A |
3970090 | Loiacono | Jul 1976 | A |
4022209 | Nehring | May 1977 | A |
4063548 | Klatt et al. | Dec 1977 | A |
4191196 | Bradley et al. | Mar 1980 | A |
4216907 | Fuller | Aug 1980 | A |
4217911 | Layton | Aug 1980 | A |
4236520 | Anderson | Dec 1980 | A |
4248214 | Hannah et al. | Feb 1981 | A |
4367740 | Evanoski | Jan 1983 | A |
4370983 | Lichtenstein | Feb 1983 | A |
4407301 | Streisinger | Oct 1983 | A |
4432352 | Wineland | Feb 1984 | A |
4432757 | Davis, Jr. | Feb 1984 | A |
4464172 | Lichtenstein | Aug 1984 | A |
4484585 | Baier | Nov 1984 | A |
4557255 | Goodman | Dec 1985 | A |
4567880 | Goodman | Feb 1986 | A |
4612939 | Robertson | Sep 1986 | A |
4632684 | Karbassiyoon et al. | Dec 1986 | A |
4704102 | Guthery | Nov 1987 | A |
4731060 | Catalano | Mar 1988 | A |
4738659 | Sleiman | Apr 1988 | A |
4750488 | Wuchinich et al. | Jun 1988 | A |
4813935 | Haber et al. | Mar 1989 | A |
4816020 | Brownell | Mar 1989 | A |
4872483 | Shah | Oct 1989 | A |
4998527 | Meyer | Mar 1991 | A |
5176148 | Wiest et al. | Jan 1993 | A |
5176664 | Weisman | Jan 1993 | A |
5331548 | Rollema et al. | Jul 1994 | A |
5342298 | Michaels et al. | Aug 1994 | A |
5377101 | Rollema | Dec 1994 | A |
5385563 | Gross | Jan 1995 | A |
5433216 | Sugrue et al. | Jul 1995 | A |
5449345 | Taylor et al. | Sep 1995 | A |
5480417 | Hascoet et al. | Jan 1996 | A |
5520636 | Korth et al. | May 1996 | A |
5566680 | Urion et al. | Oct 1996 | A |
5590648 | Mitchell et al. | Jan 1997 | A |
5623925 | Swenson et al. | Apr 1997 | A |
5624395 | Mikhail et al. | Apr 1997 | A |
5674238 | Sample et al. | Oct 1997 | A |
5688239 | Walker | Nov 1997 | A |
5722931 | Heaven | Mar 1998 | A |
5733230 | Sawchuck et al. | Mar 1998 | A |
5772628 | Bacich et al. | Jun 1998 | A |
5788631 | Fiddian-Green | Aug 1998 | A |
5792042 | Cohen et al. | Aug 1998 | A |
5800407 | Eldor | Sep 1998 | A |
5823972 | McRae | Oct 1998 | A |
5855549 | Newman | Jan 1999 | A |
5858003 | Atala | Jan 1999 | A |
5865815 | Tihon | Feb 1999 | A |
5868135 | Kaufman | Feb 1999 | A |
5887593 | Levius | Mar 1999 | A |
5924984 | Rao | Jul 1999 | A |
5954696 | Ryan | Sep 1999 | A |
5997474 | Batchelor | Dec 1999 | A |
6001060 | Churchill et al. | Dec 1999 | A |
6004305 | Hursman et al. | Dec 1999 | A |
6021781 | Thompson et al. | Feb 2000 | A |
6022955 | Sarin et al. | Feb 2000 | A |
6048308 | Strong | Apr 2000 | A |
6056699 | Sohn et al. | May 2000 | A |
6063045 | Wax et al. | May 2000 | A |
6071230 | Henalla | Jun 2000 | A |
6086549 | Nelse et al. | Jul 2000 | A |
6110099 | Benderev | Aug 2000 | A |
6119697 | Engel et al. | Sep 2000 | A |
6120438 | Rizvi | Sep 2000 | A |
6129330 | Guala | Oct 2000 | A |
6156017 | Shieh | Dec 2000 | A |
6162201 | Cohen et al. | Dec 2000 | A |
6258060 | Willard | Jul 2001 | B1 |
6258087 | Edwards | Jul 2001 | B1 |
6283987 | Laird | Sep 2001 | B1 |
6315711 | Conway et al. | Nov 2001 | B1 |
6358229 | Tihon | Mar 2002 | B1 |
6396416 | Kuusela et al. | May 2002 | B1 |
6434418 | Neal et al. | Aug 2002 | B1 |
6447462 | Wallace et al. | Sep 2002 | B1 |
6461332 | Mosel et al. | Oct 2002 | B1 |
6579266 | Mosel et al. | Jun 2003 | B2 |
6666828 | Greco et al. | Dec 2003 | B2 |
6699175 | Miller | Mar 2004 | B2 |
6719709 | Whalen et al. | Apr 2004 | B2 |
6720887 | Zunti | Apr 2004 | B1 |
20010045355 | Gephart et al. | Nov 2001 | A1 |
20020111586 | Mosel | Aug 2002 | A1 |
20020115906 | Miller | Aug 2002 | A1 |
20020147423 | Burbank et al. | Oct 2002 | A1 |
20020165521 | Cioanta et al. | Nov 2002 | A1 |
20020198506 | Whalen et al. | Dec 2002 | A1 |
20030023134 | Tracey | Jan 2003 | A1 |
20030023144 | Tracey et al. | Jan 2003 | A1 |
20030027326 | Ulmsten et al. | Feb 2003 | A1 |
20030028074 | Tracey et al. | Feb 2003 | A1 |
20030028075 | Ulmsten et al. | Feb 2003 | A1 |
20030028159 | Tracey et al. | Feb 2003 | A1 |
20030163086 | Denyer et al. | Aug 2003 | A1 |
20030181897 | Thomas et al. | Sep 2003 | A1 |
20030208183 | Whalen et al. | Nov 2003 | A1 |
20040176747 | Feneley | Sep 2004 | A1 |
Number | Date | Country |
---|---|---|
42 34 640 | Apr 1994 | DE |
196 17 854 | Nov 1997 | DE |
298 15 815 | Jan 1999 | DE |
0608593 | Aug 1994 | EP |
0878166 | Nov 1998 | EP |
2 075 841 | Nov 1981 | GB |
2261169 | May 1993 | GB |
WO 9604847 | Feb 1996 | WO |
WO 9717909 | May 1997 | WO |
WO 9749077 | Dec 1997 | WO |
WO 0023127 | Apr 2000 | WO |
WO 0117469 | Mar 2001 | WO |
WO 0128607 | Apr 2001 | WO |
Number | Date | Country | |
---|---|---|---|
20040133067 A1 | Jul 2004 | US |
Number | Date | Country | |
---|---|---|---|
60372579 | Apr 2002 | US | |
60302069 | Jun 2001 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10183790 | Jun 2002 | US |
Child | 10674452 | US |